Abstract:Background: Anxiety symptoms usually worsen depression and functional impairment. The present study was aimed to evaluate the impact of escitalopram on social function and quality of life in major depressive disorder (MDD) patients with anxiety symptoms. Patients and methods: Adult MDD patients with functional impairment (Sheehan Disability Scale [SDS] score >= 9) and anxiety symptoms (Hamilton Anxiety Rating Scale [HAM-A] score >= 14) received escitalopram (10-20 mg/day) for 8 weeks. Symptom status was assessed by SDS, Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form, Montgomery-Asberg Depression Rating Scale (MADRS), HAM-A, and Quick Inventory of Depressive Symptomatology Self Report scales. Safety was evaluated by treatment-emergent adverse events (TEAEs). Results: Overall, 208 (79.7%) of 261 enrolled patients completed the 8-week treatment. Mean (SD) SDS and Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form total scores were 17.4 (5.87) and 39.3 (14.43) at baseline, which improved to 7.6 (6.71) and 61.6 (15.80), respectively, at week 8. Totally, 59.2% of patients achieved functional remission (SDS <= 6) and 61.7% of patients achieved depression remission (MADRS <= 10) at week 8; 48.1% of patients achieved both functional and depression remission (SDS <= 6 and MADRS <= 10). The change in SDS total score was positively correlated with the change in MADRS and HAM-A total scores at each visit. Patient's baseline SDS score was related with depression score (regression coeflicient=0.40582, y=0.0005); remission of SDS was statistically related to a reduction of week 2 and week 6 HAM-A score (p<0.0001) and reduction of MADRS score (p<0.0001). Overall, 25.7% of patients reported r 1 TEAEs. Most frequently reported TEAEs were nausea (5.8%), diarrhea (2.3%), and dizziness (2.7%). Most TEAEs were mild to moderate in severity. Four patients reported serious TEAEs, two patients reported suicide attempts, and one patient completed suicide. Conclusion: Escitalopram (10-20 mg/day) treatment was efficacious in reducing depression, improving social function, and quality of life in MDD patients with anxiety symptoms. No new safety signals were identified.

Clinical effect of reboxetine in the treatment of anxiety in depressive patients

Randomized,multicenter,double blind comparative trial of reboxetine in the treatment of depression with or without anxiety

Comparison of Reboxetine with Fluoxetine in Treatment of Depression: a Randomized, Double-Blind, Multicenter Study

Treatment of Depressive Outpatient with Venlafaxine:An Open Clinical Trial

A comparative study of treatment of depression:Mirtazapine vs.fluoxepine

A Randomized and Double-Blind Comparison with Reboxetine and Citalopram in Patients with Retardant Depressive Disorder

The efficacy and safety of venlafaxine XR in treating patients with major depression in a multicenter,open-label, 16 week study

A comparison study of sertraline,venlafxin and alprazolam in treatment of generalized anxiety disorder

Bupropion SR in the treatment of depression comorbid with anxiety:a randomized,double-blind clinical trial

Research on the Effect of Escitalopram and Venlafaxine in the Treatment of Patients with Initial Diagnosis of Major Depressive Disorder

Efficacy of fluoxetine combined with psychological intervention for treatment of depressive patients with insomnia

Escitalopram and sertraline in treatment of depression with anxiety

Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety.

Clinical effects of venlafaxine in treatment of depressive disorder associated with anxiety and its impact factors

Bupropion SR and fluoxetine in treatment of depression in multicenter clinical trial

ComParison of different treatment regimens for refractory dePression efficacy

A Comparison Study of Citalopram Versus Paroxetine in Treatment of Generalized Anxiety Disorder

A controlled study in the treatment of depression with escitalopram and paroxetine

Promoting the hippocampal PPARα expression participates in the antidepressant mechanism of reboxetine, a selective norepinephrine reuptake inhibitor

Study of Bupropion Hydrochloride Tablet and Fluoxetine in Treatment of Depression Multicenter Clinical Trial

Clinical Research on Treatment of Depression with Electric Acupuncture and SSRI